Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Oral Peanut Immunotherapy (PNOIT)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Wayne G. Shreffler MD, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT01324401
First received: August 12, 2010
Last updated: November 13, 2013
Last verified: November 2013

August 12, 2010
November 13, 2013
March 2011
August 2014   (final data collection date for primary outcome measure)
Tolerance [ Time Frame: at least 36 months ] [ Designated as safety issue: No ]
Tolerance will be defined in this study as a loss of clinical sensitivity to peanut. Subjects will be considered to have achieved tolerance if the post treatment eliciting dose (ED), defined by the double blind placebo controlled food challenge, is five fold increase from the ED of baseline.
Same as current
Complete list of historical versions of study NCT01324401 on ClinicalTrials.gov Archive Site
  • Desensitization [ Time Frame: at least 36 months ] [ Designated as safety issue: Yes ]
    A five-fold increase in ED defined by OFC at the conclusion of maintenance therapy
  • The frequency of side-effects and their relationship to other variables [ Time Frame: at least 36 months ] [ Designated as safety issue: Yes ]
  • A significantly lower frequency of accidental ingestion reactions compared to controls [ Time Frame: at least 36 months ] [ Designated as safety issue: Yes ]
  • A longitudinal suppression of end-point skin testing by 2 log dilution. [ Time Frame: at least 36 months ] [ Designated as safety issue: Yes ]
  • A longitudinal suppression of peanut-specific basophil activation by 1.5 log dilution [ Time Frame: at least 36 months ] [ Designated as safety issue: Yes ]
  • A longitudinal doubling of peanut-specific IgG4 [ Time Frame: at least 36 months ] [ Designated as safety issue: Yes ]
  • A longitudinal increase of Ara h 2-specific IgG+ B cells by >1.5 SD [ Time Frame: at least 36 months ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Oral Peanut Immunotherapy
Oral Peanut Immunotherapy

Peanut allergy is one of the most serious food allergies because of its life long persistence, and the potential for severe allergic reactions. Effective oral immunotherapy would benefit patients by reducing the likelihood that they will have life-threatening accidental allergic reactions. This research study is being done to develop an effective oral immunotherapy treatment for patients with peanut allergy.

Our hypothesis is that chronic antigen exposure during peanut oral immunotherapy (OIT) will induce beneficial changes in the specific immune response, including: 1) anergy of IgE effector immune cells (e.g., mast cells, basophils) resulting in clinical desensitization; 2) induction of de novo, long lived (memory) B cell responses that antagonize specific IgE and confer immune tolerance. The investigators will test this hypothesis in the following specific aims:

  1. Induce desensitization in peanut allergic subjects with peanut OIT and evaluate the safety of the peanut OIT desensitization protocol.
  2. Induce long-standing tolerance in peanut allergic subjects with maintenance peanut OIT and evaluate the efficacy of allergen-specific testing to predict tolerance.
  3. Longitudinally evaluate basophil and mast cell reactivity in subjects receiving peanut OIT and their relationship to the induction of desensitization.
  4. Longitudinally evaluate the allergen-specific B-cell repertoire in subjects receiving peanut OIT and its relationship to the induction of tolerance.
Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Peanut Allergy
Drug: Peanut flour OIT
Patients will receive daily escalating dosages as determined in the modified rush phase as stated in the protocol. The dosage will be escalated until a daily dose of 4000 mg is reached. A Double-blind, placebo-controlled food challenge will then consist of two challenges performed on the same day. One challenge will consist of 7 doses of peanut given every 10-20 minutes in increasing amounts up to a total of 10 grams of whole peanut (5 grams of peanut protein) masked by inclusion in vehicle food. The other challenge will consist of placebo material given similarly.
  • No Intervention: Control
    The subjects enrolled in the observational control group will have follow-up visits every 6 months. Each visit will involve a medical history and physical examination.
  • Experimental: Peanut OIT
    Intervention: Drug: Peanut flour OIT
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
32
August 2015
August 2014   (final data collection date for primary outcome measure)

Inclusion criteria:

  1. Diagnosis of peanut allergy by a positive prick skin test to peanut (> 8 mm reaction wheal) or CAP FEIA >10 and a history of objective clinical symptoms within one hour after ingestion of peanuts
  2. Ability to provide informed consent.
  3. Males and females of all ethnic/racial groups between 7 and 21 years who are otherwise healthy.

Exclusion criteria:

  1. Clinical history of a severe anaphylactic reaction known or suspected to be caused by ingestion of peanut that required treatment with 2 or more administrations of epinephrine or hospitalization
  2. Moderate to Severe Asthma as defined using the Impairment or Risk Criteria of the current NHBLI Guidelines for the Diagnosis and Management of Asthma (http://www.nhlbi.nih.gov/guidelines/asthma/)
  3. Poorly controlled Asthma as defined using the Control Criteria of the current NHBLI Guidelines for the Diagnosis and Management of Asthma (http://www.nhlbi.nih.gov/guidelines/asthma/)
  4. Diagnosis of other severe or complicating medical problems
  5. Autoimmune or chronic immune or gastrointestinal inflammatory conditions, including Celiac Disease, Inflammatory Bowel Disease and Eosinophilic Gastrointestinal Disorders
  6. Primary Immune Deficiency
  7. Use of beta blockers, angiotension converting enzyme inhibitors, or monoamine oxidase inhibitors
  8. Women of childbearing potential who are pregnant, planning to become pregnant, or breastfeeding
  9. Use within the past year of other systemic immunomodulatory treatment, including allergen immunotherapy, use of biologics with an immune target, including Xolair
Both
7 Years to 21 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01324401
2010P000609
No
Wayne G. Shreffler MD, Massachusetts General Hospital
Massachusetts General Hospital
Not Provided
Principal Investigator: Wayne G Shreffler, MD, PhD Massachusetts General Hospital
Massachusetts General Hospital
November 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP